Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship

Published: March 11, 2024

pre-transplant cv evaluation  image
  • Hematopoietic stem cell transplantation (HSCT) can cure various disorders but poses cardiovascular (CV) risks, especially for older patients and those with CV diseases. Cardiovascular evaluations are crucial in pre-transplant assessments, but guidelines are lacking.
  • This statement summarizes the data on transplant-related complications and provides guidance for CV management throughout the HSCT process.
  • Long-term CV management of HSCT survivors includes optimizing risk factors, monitoring, and maintaining a low threshold for evaluating CV causes of symptoms.

Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation

Salim Hayek, MD, a cardiovascular specialist in cardio-oncology from the UTMB Health is joined by Amelia Langston, MD, a hematology and medical oncology specialist from Emory University to discuss their new AHA scientific statement on the cardiovascular management of patients undergoing hematopoietic stem cell transplantation (HSCT). They review the phases of HCST, the incidence of cardiovascular complications, long-term management, and the significance of survivorship post-transplant.